Prime Medicine, Inc.
PRMEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePrime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. The $671.1M market capitalization puts PRME squarely in small-cap range for its industry. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Market Cap
$671.1M
Beta
2.35
P/E (TTM)
—
P/E (Fwd)
-4.19
EPS (TTM)
$-1.05
EPS (Fwd)
$-0.88
ROE
-373.3%
ROA
-46.5%
Cash
$95.1M
Total Debt
$112.5M
Free CF
-$75.8M
52W Change
-10.2%
Annual Financials
Cash vs Debt
Where PRME stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, PRME finished 3.78% above its 150-day moving average ($3.44) and 0.85% above its 200-day moving average ($3.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRME overbought or oversold?
At the September 2, 2026 close, PRME's RSI(14) was 58.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $95.1M in cash, though total debt stands at $112.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$75.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -373.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Prime Medicine, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PRME.